Keywords
bladder cancer
multiparametric MRI
staging
neoplasm invasion
How to Cite
Abstract
Multiparametric magnetic resonance imaging with VI-RADS is a newly discussed method of diagnosing bladder cancer. There are more studies suggesting implementation of mpMRI with VI-RADS to the modern scheme of treating bladder cancer. It requires much more observation and trials to give a final recommendations. The aim of the summary is to present VI-RADS scale and possibilities that appear with the method. Many studies, that were made by departments of urology or radiology, showed promising results.
Background: estimation of bladder cancer depends on proper tumor staging, grading and assessment of its biological potential. It is provided by a multimodal approach using clinical, histopathological and radiological methods. Development of MRI provides the best imaging technique for locoregional staging in several other tumors. Lately it was adjusted in BCa preoperative evaluation leading to significant improvement in differentiating patients with NMIBCs and MIBCs.
Objective: this article aims to approximate the fundamentals of MRI in BCa and to provide an overview of the available data on the role of VI-RADS score in the diagnostic pathway of bladder cancer.
References
(1) Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy 2021. Website: http://onkologia.org.pl/raporty/.
(2) Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63(2):234--241. DOI:10.1016/j.eururo.2012.07.033.
(3) Veskimäe E, Espinos EL, Bruins HM, et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol 2019; 2(6):625-642. DOI:10.1016/j.euo.2019.09.003.
(4) Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021; 79(1):82-104. DOI:10.1016/j.eururo.2020.03.055.
(5) Delli Pizzi A, Mastrodicasa D, Marchioni M, et al. Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach. Eur Radiol 2020; 10.1007/s00330-020-07473-6. [published on-line ahead of print, 2020 Nov 19]. DOI:10.1007/s00330-020-07473-6.
(6) Wang H, Luo C, Zhang F, et al. Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Detrusor Muscle Invasion. Radiology 2019; 291(3):668-674. DOI:10.1148/radiol.2019182506.
(7) Gordon PC, Thomas F, Noon AP, Rosario DJ, Catto JWF. Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. Eur Urol Focus 2019; 5(4):650-657. DOI:10.1016/j.euf.2017.10.004.
(8) Ark JT, Keegan KA, Barocas DA, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int 2014; 113(6):894-899. DOI:10.1111/bju.12245.
(9) de Haas RJ, Steyvers MJ, Fütterer JJ. Multiparametric MRI of the bladder: ready for clinical routine? AJR Am J Roentgenol 2014; 202(6):1187-1195. DOI:10.2214/AJR.13.12294.
(10) Panebianco V, Narumi Y, Altun E, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018; 74(3):294-306. DOI:10.1016/j.eururo. 2018.04.029.
(11) Kim SH. Radiology Illustrated: Uroradiology 2nd ed. Heidelberg: Springer Science & Business Media. Berlin 2016.
(12) American Urological Association. Urinary Bladder: Lamina Propria. Website: https://www.auanet.org/education/auauniversity/education-products-and-resources/pathology-for-urologists/normal-histology-and-important-histo-anatomic-structures/urinary -bladder -lamina-propri.
(13) Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. European Urology 2021; 79(1):62-79. DOI:10.1016/j.eururo.2020.05.042.
(14) Panebianco V, Barchetti F, de Haas RJ, et al. Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging. Eur Urol Focus 2016; 2(2):113--121. DOI:10.1016/j.euf.2016.04.010.
(15) Verma S, Rajesh A, Prasad SR, et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012; 32(2):371-387. DOI:10.1148/rg.322115125.
(16) de Haas RJ, Steyvers MJ, Fütterer JJ. Multiparametric MRI of the bladder: ready for clinical routine? AJR Am J Roentgenol 2014; 202(6):1187-1195. DOI:10.2214/AJR.13.12294.
(17) El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 2012; 110(11 Pt B):E622-E627. DOI:10.1111/j.1464-410X.2012.11345.x.
(18) Wang HJ, Pui MH, Guan J, et al. Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. AJR Am J Roentgenol 2016; 207(4):797--803. DOI:10.2214/AJR.16.16283.
(19) Ueno Y, Tamada T, Takeuchi M, et al. VI-RADS: Multiinstitutional Multireader Diagnostic Accuracy and Interobserver Agreement Study. AJR Am J Roentgenol 2021; 216(5):1257--1266. DOI:10.2214/AJR.20.23604.
(20) Carando R, Afferi L, Marra G, et al. The effectiveness of multiparametric magnetic resonance imaging in bladder cancer (Vesical Imaging-Reporting and Data System): A systematic review. Arab J Urol 2020; 18(2):67-71. DOI:10.1080/2090598X. 2020.1733818.
(21) Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y. The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology 2018; 286(2):502-511. DOI:10.1148/radiol.2017171028.
(22) Woo S, Panebianco V, Narumi Y, et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020; 3(3):306-315. [published correction appears in Eur Urol Oncol 2020 Dec; 3(6):811]. DOI:10.1016/j.euo.2020.02.007.
(23) Del Giudice F, Pecoraro M, Vargas HA, et al. Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers (Basel) 2020; 12(10):2994. DOI:10.3390/cancers12102994.
(24) Kim SH. Validation of vesical imaging reporting and data system for assessing muscle invasion in bladder tumor. Abdom Radiol (NY) 2020; 45(2):491-498. DOI:10.1007/s00261-019-02190-1.
(25) Barchetti G, Simone G, Ceravolo I, et al. Multiparametric MRI of the bladder: inter-observer agreement and accuracy with the Vesical Imaging-Reporting and Data System (VI-RADS) at a single reference center. Eur Radiol 2019; 29(10):5498-5506. DOI:10.1007/s00330-019-06117-8.
(26) Del Giudice F, Barchetti G, De Berardinis E, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020; 77(1):101-109. DOI:10.1016/j.eururo.2019.09.029.
(27) Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol 2019; 92(1104):20190401. DOI:10.1259/bjr.20190401.
(28) Kausch I, Sommerauer M, Montorsi F, et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol 2010; 57(4):595-606. DOI:10.1016/j.eururo. 2009.11.041.
(29) Daneshmand S, Ahmadi H, Huynh LN, Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 2012; 80(6):1313-1318. DOI:10.1016/j.urology.2012.07.056.
(30) Rosenkrantz AB, Friedman KP, Ponzo F, et al. Prospective Pilot Study to Evaluate the Incremental Value of PET Information in Patients With Bladder Cancer Undergoing 18F-FDG Simultaneous PET/MRI. Clin Nucl Med 2017; 4(1):e8-e15. DOI:10.1097/RLU.0000000000001432.
(31) Babjuk M, Burger M, Compérat E, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Presented at the EAU Annual Congress Amsterdam 2020. EAU Guidelines Office.
This work is licensed under a Creative Commons Attribution 4.0 International License.